ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1392

Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers

Margaret Essien and Ram Singh, UCLA David Geffen School of Medicine, Los Angeles, CA

Meeting: ACR Convergence 2025

Keywords: Epidemiology, Mortality, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Sjögren’s disease (SjD), an autoimmune condition with chronic inflammation in exocrine glands, is associated with increased risks of cancers. The impact of cancer on mortality from SjD is not well documented. Here, we assessed trends associated with mortality from cancer in SjD across the US over a 22-year period.

Methods: This is a population-based study using a national mortality database and census data covering all U.S. residents. We calculated age-standardized mortality rates (ASMR) for cancer in SjD (SjD-C) and all-cancers, overall and by demographic variables. For comparison, we calculated ASMRs for SjD, non-Hodgkin’s lymphoma that is the commonest malignancy in SjD, and another autoimmune disease dermatopolymyositis. We performed joinpoint trend analysis to estimate annual percent change (APC) in ASMRs, and Chi-square statistics with Yates’s correction to compare changes in different cancer deaths over time.

Results: SjD was recorded as a cause of death in 7,817 decedents from 1999 through 2020. Of these, 1,395 (17.8%) had both SjD AND cancer recorded as multiple causes of death. During the same time-period, the number of all-cancer deaths was 8,096,904. The ASMRs for SjD-C initially showed a decreasing trend (p=NS), but significantly increased in the last decade at an APC of 4.04% (95% CI, 2.14-13.43; 2007-2020). In contrast, the all-cancers ASMRs decreased throughout the 22-year period. The average APC for the entire 1999-2020 was 1.54% (95% CI, 0.43-3.19) for SjD-C ASMR and -1.50% (95% CI, -1.58% to -1.46%) for all-cancer ASMRs. Mortality from dermatopolymyositis-associated cancers and non-Hodgkin’s lymphoma decreased during the study period. The SjD-C mortality rates were higher in females than males, non-Hispanic whites than other race/ethnic groups, ≥65-years old than in 0-64-years, and decedents in the West than in other census regions. Proportions of hematological cancer deaths decreased, whereas lung cancer deaths increased in SjD during the last decade.

Conclusion: In this nationwide, population-based study, cancer mortality in SjD exhibited an increasing trend in the last decade, while all-cancer mortality continually decreased. Prospective, population-based studies are needed to identify causes underlying this increase.

Supporting image 1Trends in ASMR for SjD+cancer and all-cancers, and Ratio of SjD+cancer to all cancer Mortality Rates, 1999-2020.

Green bars indicate a statistically significant decreasing trend, Red bars indicate a statistically significant increasing trend, and White bars indicate that the trend is not statistically significant.. *p < 0.05.


Disclosures: M. Essien: None; R. Singh: None.

To cite this abstract in AMA style:

Essien M, Singh R. Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/cancer-mortality-in-sjogrens-disease-disproportionate-increase-in-mortality-from-cancers-in-sjogrens-disease-relative-to-all-cancers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cancer-mortality-in-sjogrens-disease-disproportionate-increase-in-mortality-from-cancers-in-sjogrens-disease-relative-to-all-cancers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology